Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Genix Pharmaceuticals

TSXV:GENX
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GENX
TSXV
CA$9M
Market Cap
  1. Home
  2. CA
  3. Household
Company description

Genix Pharmaceuticals Corporation manufactures and converts dietary supplements and neutraceuticals for the natural health care products and supplement industries primarily in Canada and the United States. The last earnings update was 10 days ago. More info.


Add to Portfolio Compare Print
  • Genix Pharmaceuticals has significant price volatility in the past 3 months.
GENX Share Price and Events
7 Day Returns
20%
TSXV:GENX
4.1%
CA Personal Products
2.5%
CA Market
1 Year Returns
260%
TSXV:GENX
-30.9%
CA Personal Products
-24.8%
CA Market
GENX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genix Pharmaceuticals (GENX) 20% 63.6% - 260% 300% 260%
CA Personal Products 4.1% -14.2% -16.6% -30.9% -34.6% 1.5%
CA Market 2.5% -20.8% -24.7% -24.8% -22.2% -17%
1 Year Return vs Industry and Market
  • GENX outperformed the Personal Products industry which returned -30.9% over the past year.
  • GENX outperformed the Market in Canada which returned -24.8% over the past year.
Price Volatility
GENX
Industry
5yr Volatility vs Market

GENX Value

 Is Genix Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Genix Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Genix Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Genix Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is CA$0.18.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genix Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genix Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:GENX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2020-01-31) in CAD CA$0.00
TSXV:GENX Share Price ** TSXV (2020-04-03) in CAD CA$0.18
North America Personal Products Industry PE Ratio Median Figure of 20 Publicly-Listed Personal Products Companies 12.66x
Canada Market PE Ratio Median Figure of 497 Publicly-Listed Companies 10.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genix Pharmaceuticals.

TSXV:GENX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:GENX Share Price ÷ EPS (both in CAD)

= 0.18 ÷ 0.00

-41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genix Pharmaceuticals is loss making, we can't compare its value to the North America Personal Products industry average.
  • Genix Pharmaceuticals is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Genix Pharmaceuticals's expected growth come at a high price?
Raw Data
TSXV:GENX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Personal Products Industry PEG Ratio Median Figure of 7 Publicly-Listed Personal Products Companies 1.32x
Canada Market PEG Ratio Median Figure of 233 Publicly-Listed Companies 0.68x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Genix Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Genix Pharmaceuticals's assets?
Raw Data
TSXV:GENX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2020-01-31) in CAD CA$0.00
TSXV:GENX Share Price * TSXV (2020-04-03) in CAD CA$0.18
Canada Personal Products Industry PB Ratio Median Figure of 16 Publicly-Listed Personal Products Companies 0.89x
Canada Market PB Ratio Median Figure of 2,360 Publicly-Listed Companies 0.99x
TSXV:GENX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:GENX Share Price ÷ Book Value per Share (both in CAD)

= 0.18 ÷ 0.00

-84.51x

* Primary Listing of Genix Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genix Pharmaceuticals has negative assets, we can't compare the value of its assets to the CA Personal Products industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Genix Pharmaceuticals's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Personal Products industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Genix Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Genix Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

GENX Future Performance

 How is Genix Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genix Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genix Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Genix Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Genix Pharmaceuticals's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Genix Pharmaceuticals's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:GENX Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 19%
Canada Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
Canada Market Earnings Growth Rate Market Cap Weighted Average 5.1%
Canada Market Revenue Growth Rate Market Cap Weighted Average 3.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:GENX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:GENX Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2020-01-31 0 0 0
2019-10-31 0 0 0
2019-07-31 0 0 0
2019-04-30 0 0 0
2019-01-31 0 0 0
2018-10-31 0 0 0
2018-07-31 0 0 0
2018-04-30 0 0 0
2018-01-31 0 0 0
2017-10-31 0 0 0
2017-07-31 1 0 0
2017-04-30 1 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Genix Pharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Genix Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:GENX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Genix Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:GENX Past Financials Data
Date (Data in CAD Millions) EPS *
2020-01-31 0.00
2019-10-31 0.00
2019-07-31 0.00
2019-04-30 0.00
2019-01-31 0.00
2018-10-31 0.00
2018-07-31 0.00
2018-04-30 0.00
2018-01-31 0.00
2017-10-31 0.00
2017-07-31 0.00
2017-04-30 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Genix Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Genix Pharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  2. Genix Pharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Genix Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genix Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

GENX Past Performance

  How has Genix Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genix Pharmaceuticals's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genix Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Genix Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Genix Pharmaceuticals's 1-year growth to the North America Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Genix Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genix Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:GENX Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2020-01-31 0.06 -0.16 0.09
2019-10-31 0.14 -0.16 0.08
2019-07-31 0.24 -0.13 0.14
2019-04-30 0.39 -0.12 0.17
2019-01-31 0.42 -0.04 0.12
2018-10-31 0.42 -0.03 0.12
2018-07-31 0.43 0.02 0.10
2018-04-30 0.09 -0.01 -0.13
2018-01-31 0.23 -0.02 0.01
2017-10-31 0.42 -0.03 0.11
2017-07-31 0.57 -0.09 0.24
2017-04-30 1.01 -0.11 0.57
2017-01-31 0.93 -0.15 0.53
2016-10-31 0.92 -0.15 0.51
2016-07-31 0.85 -0.26 0.55
2016-04-30 0.77 -0.42 0.59
2016-01-31 0.74 -0.48 0.63
2015-10-31 0.65 -0.55 0.64
2015-07-31 0.57 -0.47 0.49
2015-04-30 0.52 -0.39 0.40
2015-01-31 0.45 -0.07 0.09
2014-10-31 0.37 0.03 0.03
2014-07-31 0.52 -0.13 0.21
2014-04-30 0.48 -0.01 0.13
2014-01-31 0.50 -0.20 0.31
2013-10-31 0.60 -0.19 0.29
2013-07-31 0.40 -0.02 0.11
2013-04-30 0.53 -0.08 0.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Genix Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Genix Pharmaceuticals has efficiently used its assets last year compared to the North America Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Genix Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Genix Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genix Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

GENX Health

 How is Genix Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genix Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genix Pharmaceuticals's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Genix Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genix Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Genix Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genix Pharmaceuticals Company Filings, last reported 2 months ago.

TSXV:GENX Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2020-01-31 -0.08 0.04 0.01
2019-10-31 -0.04 0.02 0.03
2019-07-31 -0.05 0.01 0.01
2019-04-30 -0.05 0.00 0.01
2019-01-31 0.08 0.00 0.02
2018-10-31 0.12 0.00 0.07
2018-07-31 0.11 0.00 0.04
2018-04-30 0.03 0.00 0.10
2018-01-31 0.13 0.00 0.10
2017-10-31 0.12 0.00 0.10
2017-07-31 0.22 0.00 0.09
2017-04-30 0.31 0.00 0.17
2017-01-31 0.34 0.00 0.11
2016-10-31 0.37 0.00 0.11
2016-07-31 0.37 0.00 0.08
2016-04-30 0.39 0.00 0.12
2016-01-31 0.51 0.00 0.28
2015-10-31 0.51 0.00 0.27
2015-07-31 0.60 0.00 0.28
2015-04-30 0.76 0.00 0.46
2015-01-31 0.62 0.00 0.28
2014-10-31 0.66 0.00 0.36
2014-07-31 0.67 0.00 0.53
2014-04-30 0.78 0.00 0.65
2014-01-31 0.60 0.00 0.36
2013-10-31 0.57 0.00 0.34
2013-07-31 0.78 0.00 0.34
2013-04-30 0.78 0.00 0.32
  • Genix Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Genix Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Genix Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Genix Pharmaceuticals has less than a year of cash runway if free cash flow continues to reduce at historical rates of -14.1% each year.
X
Financial health checks
We assess Genix Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genix Pharmaceuticals has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

GENX Dividends

 What is Genix Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genix Pharmaceuticals dividends.
If you bought CA$2,000 of Genix Pharmaceuticals shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genix Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genix Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:GENX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2%
Canada Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 4.7%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.3%
Canada Bottom 25% Dividend Yield 25th Percentile 2.7%
Canada Top 25% Dividend Yield 75th Percentile 8.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genix Pharmaceuticals has not reported any payouts.
  • Unable to verify if Genix Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genix Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genix Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Genix Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genix Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genix Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

GENX Management

 What is the CEO of Genix Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sina Pirooz
TENURE AS CEO 1.1 years
CEO Bio

Mr. Sina Salehi Pirooz has been Director of Alta Natural Herbs & Supplements Ltd. since August 3, 2018 and its Chief Executive Officer since March 11, 2019. Mr. Pirooz is the Owner of Coal Harbour Compounding Pharmacy and President of SP RX Services. Mr. Pirooz is a registered and practicing pharmacist and a professional member of the College of Pharmacists of British Columbia since 2003. Mr. Pirooz has over 18 years experience in the international pharmaceuticals industry and has been a professional member of the College of Pharmacists of British Columbia since 2003. Mr. Pirooz has provided consulting, pharmacist and pharmacy management services to many of Canada's leading pharmacies and drug stores including Rexall Drugs, Pharmasave and Guardian Pharmacies. He is also actively engaged in the sales, marketing and export of pharmaceuticals, OTC drugs and health supplements to the Middle East.

CEO Compensation
  • Insufficient data for Sina to compare compensation growth.
  • Insufficient data for Sina to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team

Haofang Song

TITLE
COMPENSATION
CA$16K

Sina Pirooz

TITLE
CEO & Director
TENURE
1.1 yrs

Jamie Lewin

TITLE
CFO & Director
AGE
69
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure of the Genix Pharmaceuticals board of directors in years:

1
Average Tenure
  • The average tenure for the Genix Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Sina Pirooz

TITLE
CEO & Director
TENURE
1.7 yrs

Jamie Lewin

TITLE
CFO & Director
AGE
69
TENURE
1.1 yrs

Conny Lin

TITLE
Director
TENURE
0.8 yrs

Kevin Bottomley

TITLE
Independent Director
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Genix Pharmaceuticals individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
22. Jan 20 Buy Kevin Bottomley Individual 22. Jan 20 22. Jan 20 5,000 CA$0.08 CA$400
X
Management checks
We assess Genix Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genix Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

GENX News

Simply Wall St News

What Kind Of Shareholder Owns Most Genix Pharmaceuticals Corporation (CVE:GENX) Stock?

Genix Pharmaceuticals is a smaller company with a market capitalization of CA$1.3m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that institutional investors have not yet purchased shares. … See our latest analysis for Genix Pharmaceuticals TSXV:GENX Ownership Summary, August 21st 2019 What Does The Lack Of Institutional Ownership Tell Us About Genix Pharmaceuticals?

Simply Wall St -

What Kind Of Share Price Volatility Should You Expect For Genix Pharmaceuticals Corporation (CVE:GENX)?

If you're interested in Genix Pharmaceuticals Corporation (CVE:GENX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

GENX Company Info

Description

Genix Pharmaceuticals Corporation manufactures and converts dietary supplements and neutraceuticals for the natural health care products and supplement industries primarily in Canada and the United States. The company offers herbal, botanical, and marine-based neutraceuticals. It also acts as a contract manufacturer/converter of raw material powders with all conversion from powders to capsules to bottling and packaging. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is headquartered in Vancouver, Canada.

Details
Name: Genix Pharmaceuticals Corporation
GENX
Exchange: TSXV
Founded: 1993
CA$9,452,562
52,514,237
Website: http://www.altanatural.ca
Address: Genix Pharmaceuticals Corporation
4665 West 10th Avenue,
Suite 403,
Vancouver,
British Columbia, V6R 2J4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV GENX Common Shares TSX Venture Exchange CA CAD 26. Nov 1993
Number of employees
Current staff
Staff numbers
0
Genix Pharmaceuticals employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 04:36
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2020/03/26
Last earnings reported: 2020/01/31
Last annual earnings reported: 2019/10/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.